HK1194996A1 - 含有黑皮質素受體配體作為活性成分的緩釋組合物 - Google Patents

含有黑皮質素受體配體作為活性成分的緩釋組合物

Info

Publication number
HK1194996A1
HK1194996A1 HK14108445.8A HK14108445A HK1194996A1 HK 1194996 A1 HK1194996 A1 HK 1194996A1 HK 14108445 A HK14108445 A HK 14108445A HK 1194996 A1 HK1194996 A1 HK 1194996A1
Authority
HK
Hong Kong
Prior art keywords
sustained
active ingredient
composition containing
receptor ligand
release composition
Prior art date
Application number
HK14108445.8A
Other languages
English (en)
Inventor
Jol Richard
Faza Laredj
Marie-Madeleine Baronnet
Didier Nourrisson
Jeremiah Harnett
Batrice Hacher
Nathalie Mondoly
Laurent Bertocchi
Original Assignee
Ipsen Pharma Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma Sas filed Critical Ipsen Pharma Sas
Publication of HK1194996A1 publication Critical patent/HK1194996A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/35—Corticotropin [ACTH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
HK14108445.8A 2011-06-14 2014-08-18 含有黑皮質素受體配體作為活性成分的緩釋組合物 HK1194996A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11290270 2011-06-14
PCT/IB2012/001588 WO2012172433A2 (en) 2011-06-14 2012-06-13 A sustained-release composition containing peptides as active ingredient

Publications (1)

Publication Number Publication Date
HK1194996A1 true HK1194996A1 (zh) 2014-10-31

Family

ID=44851715

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14108445.8A HK1194996A1 (zh) 2011-06-14 2014-08-18 含有黑皮質素受體配體作為活性成分的緩釋組合物

Country Status (14)

Country Link
US (1) US9415012B2 (zh)
EP (1) EP2720684B1 (zh)
JP (1) JP6072020B2 (zh)
KR (1) KR102038677B1 (zh)
CN (1) CN103608003B (zh)
AU (1) AU2012270024B2 (zh)
BR (1) BR112013027222B1 (zh)
CA (1) CA2833676C (zh)
ES (1) ES2718655T3 (zh)
HK (1) HK1194996A1 (zh)
MX (1) MX341642B (zh)
RU (1) RU2633483C2 (zh)
UA (1) UA114088C2 (zh)
WO (1) WO2012172433A2 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3539551T3 (da) 2011-12-29 2021-11-01 Rhythm Pharmaceuticals Inc Fremgangsmåde til behandling af melanocortin-4 receptor-associerede forstyrrelser i heterozygotiske bærere
EP2705835A1 (en) * 2012-06-08 2014-03-12 Ipsen Pharma S.A.S. Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release
AU2014227712B2 (en) 2013-03-15 2018-08-02 Rhythm Pharmaceuticals, Inc. Peptide compositions
PL2970389T3 (pl) * 2013-03-15 2021-03-08 Rhythm Pharmaceuticals, Inc. Kompozycje farmaceutyczne
EP3595638A4 (en) * 2017-03-15 2020-09-16 Cerecin Inc. MEDIUM CHAIN TRIGLYCERIDE PHARMACEUTICAL COMPOSITIONS HIGH ACTIVE INGREDIENT AND PROCESS RELATED THEREOF
JP2021523931A (ja) * 2018-03-23 2021-09-09 パラティン テクノロジーズ， インコーポレイテッド メラノコルチン受容体特異的ペプチド製剤及び消化管特異的送達方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB761061A (en) * 1952-06-21 1956-11-07 Leo Ab Method for producing preparations with protracted acth-effect and such preparations
US5665702A (en) 1995-06-06 1997-09-09 Biomeasure Incorporated Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US7276251B2 (en) * 1997-04-01 2007-10-02 Lg Life Sciences, Ltd., Inc. Sustained-release composition of drugs encapsulated in microparticles of hyaluronic acid
KR100236771B1 (ko) * 1997-04-01 2000-02-01 성재갑 히아루론산을 이용한 약물의 서방성 미세입자 제형
WO1999038536A1 (en) * 1998-01-29 1999-08-05 Poly-Med Inc. Absorbable microparticles
US6579968B1 (en) 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
CA3228910A1 (en) * 2005-07-08 2007-01-18 Ipsen Pharma S.A.S Melanocortin receptor ligands
TWI364290B (en) 2007-05-25 2012-05-21 Ipsen Pharma Sas Melanocortin receptor ligands modifled with hydantoin
EP2167112A4 (en) * 2007-06-15 2012-01-25 Ipsen Pharma Sas CYCLIC PEPTIDE MELANOCORTIN RECEPTOR LIGANDS
KR20150013339A (ko) * 2007-11-05 2015-02-04 입센 파마 에스.에이.에스 인슐린 민감성을 치료하기 위한 멜라노코르틴의 용도
RU2508093C2 (ru) 2008-07-01 2014-02-27 Нитто Денко Корпорейшн Фармацевтическая композиция, содержащая микрочастицы с поверхностным покрытием
IN2012DN00407A (zh) * 2009-08-05 2015-08-21 Pieris Ag
MX2012001513A (es) * 2009-08-05 2012-05-22 Ipsen Pharma Sas Uso de melanocortinas para tratar la dislipidemia.
EP2501225B1 (en) * 2009-11-16 2017-11-01 Ipsen Pharma S.A.S. Pharmaceutical compositions of melanocortin receptor ligands

Also Published As

Publication number Publication date
UA114088C2 (xx) 2017-04-25
JP6072020B2 (ja) 2017-02-01
AU2012270024A1 (en) 2014-01-16
KR20140041531A (ko) 2014-04-04
CA2833676A1 (en) 2012-12-20
CN103608003A (zh) 2014-02-26
MX2013013691A (es) 2014-03-05
MX341642B (es) 2016-08-29
BR112013027222B1 (pt) 2022-07-12
JP2014517030A (ja) 2014-07-17
EP2720684A2 (en) 2014-04-23
WO2012172433A2 (en) 2012-12-20
EP2720684B1 (en) 2019-01-16
CA2833676C (en) 2019-04-23
AU2012270024B2 (en) 2016-12-22
ES2718655T3 (es) 2019-07-03
BR112013027222A2 (pt) 2016-12-27
CN103608003B (zh) 2016-05-04
RU2014100909A (ru) 2015-07-20
KR102038677B1 (ko) 2019-10-30
WO2012172433A3 (en) 2013-01-31
US20140127303A1 (en) 2014-05-08
RU2633483C2 (ru) 2017-10-12
US9415012B2 (en) 2016-08-16

Similar Documents

Publication Publication Date Title
IL232345A0 (en) A stable preparation for pest control
ZA201403814B (en) Fungicidal compositions
AP3391A (en) 2-Amino-4-arylthiazole compounds as TROA1 antagonists
EP2629775A4 (en) INJECTABLE FORMULATION WITH DELAYED RELEASE
GB201216018D0 (en) Pharmacologically active compounds
HK1194996A1 (zh) 含有黑皮質素受體配體作為活性成分的緩釋組合物
ZA201206973B (en) Insecticidal compounds
ZA201309711B (en) A new therapeutical composition containing apomorphine as active ingredient
EP2582246A4 (en) BIOCIDAL COMPOSITION
ZA201304633B (en) A pharmaceutical composition
ZA201306232B (en) Pesticidal composition
ZA201404035B (en) Microcapsule containing fungicidal active ingredient
SG11201406278PA (en) Pesticidal composition
HK1204971A1 (zh) 通過雙複合激活強效抗癌活性
EP2566494A4 (en) CXCR4 RECEPTOR COMPOUNDS
ZA201403103B (en) Sustained-release preparation
ZA201207011B (en) A novel pesticidal composition
PT2489269T (pt) Composição contendo um compósito biocida
ZA201306307B (en) A fungicidal composition
GB201111490D0 (en) Biocidal composition
HK1188959A1 (zh) 磷霉素藥物組合物
IL223266A0 (en) Sustained-release formulation
AP3460A (en) Pesticidal composition
EP2628488A4 (en) PHARMACEUTICAL COMPOSITION WITH MAINTAINED RELEASE
AP3618A (en) Pesticidal composition